Cargando…

Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

OBJECTIVES: The ECOG‐ACRIN Cancer Research Group trial E2511 recently demonstrated a potential benefit for the addition of veliparib to cisplatin‐etoposide (CE) in patients with extensive stage small cell lung cancer (ES‐SCLC) in a phase II randomized controlled trial. Secondary trial endpoints incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steffen McLouth, Laurie E., Zhao, Fengmin, Owonikoko, Taofeek K., Feliciano, Josephine L., Mohindra, Nisha A., Dahlberg, Suzanne E., Wade, James L., Srkalovic, Gordan, Lash, Bradley W., Leach, Joseph W., Leal, Ticiana A., Aggarwal, Charu, Cella, David, Ramalingam, Suresh S., Wagner, Lynne I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571824/ https://www.ncbi.nlm.nih.gov/pubmed/32860331 http://dx.doi.org/10.1002/cam4.3416

Ejemplares similares

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial
por: Neal, Joel W., et al.
Publicado: (2016)

ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer
por: Cmelak, Anthony, et al.
Publicado: (2020)

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
por: Ganzel, Chezi, et al.
Publicado: (2021)

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG‐ACRIN Cancer Research Group (E1302)
por: Oswald, Laura B., et al.
Publicado: (2020)

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial
por: Murphy, Caitlin C., et al.
Publicado: (2021)

Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC
por: Varlotto, John M., et al.
Publicado: (2022)

Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)
por: Kemeny, M. Margaret, et al.
Publicado: (2022)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)
por: Ballinger, Tarah J., et al.
Publicado: (2022)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
por: Atkins, Michael B., et al.
Publicado: (2023)

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
por: Stockton, Shannon, et al.
Publicado: (2023)

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
por: Villaruz, Liza C., et al.
Publicado: (2015)

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
por: Schneider, Bryan P, et al.
Publicado: (2015)

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
por: King, Rebecca L., et al.
Publicado: (2018)

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
por: Stein, Mark N., et al.
Publicado: (2019)

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)
por: Bradbury, Angela R., et al.
Publicado: (2021)

2511. Estimating Numbers of Influenza Excess Deaths and Hospitalizations at the State-Level
por: Czaja, Christopher, et al.
Publicado: (2018)

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2022)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023)

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
por: Rapaport, Franck, et al.
Publicado: (2023)

Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)
por: Fazeli, Soudabeh, et al.
Publicado: (2021)

Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)
por: Fazeli, Soudabeh, et al.
Publicado: (2022)

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial
por: Partridge, Savannah C., et al.
Publicado: (2022)

Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)
por: Khan, Saad A., et al.
Publicado: (2021)

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
por: Nowakowski, Grzegorz S., et al.
Publicado: (2021)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
por: Litzow, Mark, et al.
Publicado: (2023)

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)
por: Swinnen, Lode J., et al.
Publicado: (2017)

Abstract No.: ABS2511: Ultrasound assessment of airway parameters and their clinical correlation to predict difficult airway and laryngoscopy.
por: Kataria, Anshika
Publicado: (2022)

Conjugation and transposon mutagenesis of Xenorhabdus griffiniae HGB2511, the bacterial symbiont of the nematode Steinernema hermaphroditum (India)
por: Alani, Omar S., et al.
Publicado: (2023)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
por: Pietanza, M. Catherine, et al.
Publicado: (2018)

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
por: Schneider, B P, et al.
Publicado: (2014)

2511: Use of an online provider learning community to assess clinical HIV/HCV/STDs-related training needs
por: Monica Barbosu, Cabiria, et al.
Publicado: (2018)

2511. Characterization of Patient Pill Preferences from a Prospective Placebo vs. Placebo Ease of Swallowability Study
por: Osborn, Zachary F, et al.
Publicado: (2019)

PB2511: CLINICAL COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN GERMANY
por: Udeze, Chuka, et al.
Publicado: (2023)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2mtpp2apbcgpsjt0n3bji87j12